Kathleen Moore, MD, MS

Experts explore the evolving landscape of ovarian cancer treatment, emphasizing the need for targeted therapies and biomarker-driven approaches.

Innovative therapies for ovarian cancer, including engineered T cells and antibody-drug conjugates, show promise in improving patient outcomes.

Explore the latest advancements in ovarian cancer treatment, focusing on combination therapies and innovative approaches for platinum-resistant patients.

Explore the importance of clinical trials for ovarian cancer treatments, highlighting innovative therapies and the need for early patient access.

PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers.

Innovative antibody drug conjugates are advancing in ovarian cancer treatment, exploring new maintenance therapies and biomarker-driven approaches for improved outcomes.

A panelist discusses how novel targeted therapies such as antibody-drug conjugates are rapidly evolving in gynecologic oncology, with multiple agents targeting different biomarkers in development, though optimal sequencing strategies remain to be determined.

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, recommending it as first-line therapy for folate receptor alpha–high tumors due to higher response rates when used earlier.